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Objective. To investigate the relationship between insulin resistance and viral load decay in nondiabetic and noncirrhotic genotype
1 chronic HCV patients during peginterferon and ribavirin treatment and the possible influence of BMI and leptin as metabolic
confounders.Methods. 75 consecutive noncirrhotic, nonobese, and nondiabetic patients with genotype 1 chronic hepatitis C treated
with peginterferon alpha 2a plus ribavirin were evaluated. HOMA-IR, serum leptin, and BMI were measured in all patients at
baseline and at weeks 12 and 48, whereas viral load was measured at the same time points and then 24 weeks after the end of
treatment.Results. HOMA-IRwas significantly associated with both BMI and leptin at baseline. During peginterferon plus ribavirin
treatment, there was a significant reduction of HOMA-IR at weeks 12 and 48 from baseline (𝑃 = 0.033 and 0.048, resp.) in patients
who achieved an early viral load decay (EVR), a trend not observed in patients who not achieved EVR. No variations during
treatment were observed regarding BMI and leptin irrespective of EVR. Conclusion. The early reduction of HOMA-IR but not of
BMI and leptin during antiviral treatment in noncirrhotic, chronic hepatitis C genotype 1 patients who achieved EVR suggests a
viral genesis of insulin resistance in patients with nonmetabolic phenotype.
1. Introduction
The standard treatment of genotype 1 chronic hepatitis Cwith
pegylated-interferon plus ribavirin is associated with a 40–
50% rate of sustained viral response (SVR) [1–3].
A number of pretreatment variables related to the virus
(hepatitis C virus genotypes 1 and 4, high viral load) and to
the host (IL-28 polymorphism, age, overweight, and meta-
bolic factors), as well as on-treatment variables (4-week neg-
ativization of viral load) have been demonstrated to affect the
response to anti-viral therapy in patients with chronic hepati-
tis C [4–7].
Among host factors, overweight and insulin resistance are
themost commonly studied since they are a possible target of
intervention. One of the open issues today is the mutual
influence of insulin resistance and viral load variations during
antiviral treatment.
The relationship between insulin resistance and hepatitis
C virus (HCV) is complex and still not completely elucidated.
HCV genotype 1 is able to directly induce insulin resistance
[8] by interfering with insulin signaling on hepatocytes [9].
Insulin resistance is a profibrogenetic stimulus; thus patients
with high insulin resistance showmore advanced liver fibrosis
than patients with low insulin resistance [10].
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There is robust evidence that antiviral treatment influ-
ences insulin resistance. Patients with SVR showed a signifi-
cant reduction of insulin resistance from baseline to the end
of follow-up compared with patients who did not achieve
SVR [11, 12].These data support the hypothesis thatHCVmay
induce insulin resistance.
On the other hand, insulin resistance can influence
antiviral response. Patients with high insulin resistance have a
slower decay of HCV viral load than patients with low insulin
resistance already in the early phase of treatment, suggest-
ing that hyperinsulinaemia reduces the cellular response to
pegylated-interferon [13]. Furthermore, lower SVR has been
observed in patients with genotype 1 chronic hepatitis C and
high insulin resistance as compared to patients with low
insulin resistance [14].
Another question is whether the insulin resistance vari-
ations during treatment are the result of a selective direct
antiviral effect (i.e., on insulin signal at the hepatocyte level)
or rather an indirect consequence of antiviral treatment on
combined metabolic factors (i.e., body mass index or
adipokine variations during treatment). It has been observed
that, in patients withHCVgenotype 1 infections, therapywith
peginterferon and ribavirin is associated with a decrease of
body weight and insulin resistance [15]. Elevated leptin levels
have been reported in patients with chronic HCV infection,
and especially in those with metabolic risk factors, but it
seems to be directly related to the degree of steatosis and of
fibrosis [16]. These data support the hypothesis of a
metabolic-related effect of antiviral therapy.However, a leptin
level reduction without BMI modification during antiviral
treatment in HCV patients has been reported [17], although
there is no conclusive evidence to answer the former issue.
With this inmind, the aimof our studywas to evaluate the
relationship between insulin resistance and viral load modi-
fications as well as the possible influence of body mass index
(BMI) and serum leptin as metabolic confounders on insulin
resistance kinetics in nondiabetic and noncirrhotic genotype
1 chronic hepatitis C patients during peginterferon alpha and
ribavirin treatment.
2. Patients and Methods
The current study was designed to analyse data from 75 con-
secutive, nondiabetic patients with genotype 1 chronic HCV
without cirrhosis who had not previously been treated with
interferon alpha and/or ribavirin and who were recruited
from two referral liver units (University of Genoa and San
Paolo Hospital, Savona, Italy).
Seventy-five consecutive, nondiabetic, and noncirrhotic
patients with genotype 1 chronic HCV who had not pre-
viously been treated with interferon alpha and/or ribavirin
were included in this study. There were 45 men (60%) and
30 women (40%), with median age of 49 years (range 26–67).
All patients had HCV-RNA levels higher than 1000 IU/mL,
increased serum alanine aminotransferase (ALT) levels at
screening, and a liver biopsy specimen taken in the 18months
prior to study entry showing chronic hepatitis. Patients were
excluded if they had HCV genotype other than type 1 infec-
tion (i.e., HCV types 2–6), biopsy-proven cirrhosis, other
causes of liver disease, hepatitis B virus infection, human
immunodeficiency virus infection, autoimmune disorders,
clinically significant cardiac or cardiovascular abnormalities,
organ grafts, systemic infections, clinically significant bleed-
ing disorders, evidence of malignant neoplastic diseases,
concomitant immunosuppressivemedication, fasting glucose
levels >7mmol/L or glucose levels >11.1mmol/L at 2 hours
after an oral intake of 75 grams of glucose (oral glucose toler-
ance test) or glycosylated hemoglobin > 48mmol/mol (6.5%)
or antidiabetic treatment, or any alcohol intake or drug abuse
within the six months prior to study entry. Patients with a
BMI ≥ 30 were also excluded from the study.
All 75 patients were treated with the same initial schedule
of peginterferon alpha-2a (Pegasys, Roche Corp. at a dose of
180 𝜇g/kg/week and ribavirin (Copegus, Roche Corp.)) either
1000mg/day (body weight < 75 kg) or 1200mg/day (body
weight > 75 kg). During treatment, patients were evaluated at
monthly intervals (i.e., blood cell count, hemoglobin levels,
platelets, thyroid function, and serum liver tests) to monitor
compliance and side effects. Patients who showed a <2log
10
drop in viral load at week 12 as compared to baseline or
those whose HCV-RNA level was positive at week 24 discon-
tinued treatment on the basis of the international guidelines.
Conversely, patients who had a ≥2log
10
drop in viral load at
week 12 as compared to baseline and whose HCV-RNA level
was negative at week 24 continued the treatment schedule for
a total of 48 weeks. The study protocol was approved by the
local Ethics Committees and patients gave written informed
consent to participate.
2.1. Virologic Assessment and Definition of On-Treatment
Response. All subjects were reactive to anti-HCV antibodies
using a third-generation enzyme immunoassay EIA (Abbott
HCV 3.0 Elisa). Serum HCV-RNA levels were quantified in
all patients at the beginning of treatment and then at weeks
4, 12, 24, 48, and 72 by using a real-time polymerase chain
reaction (PCR) (COBAS TaqMan). HCV genotype was deter-
mined using the INNO-LiPA HCV II kit (Bayer Diagnostics,
Emeryville, CA).
Patients who had a ≥2log
10
drop in viral load at week
12 as compared to baseline and whose HCV-RNA level was
negative at week 24were defined as early virologic responders
(EVR). All EVRs also had end-of-treatment response (EOTR)
defined as having negative HCV-RNA levels at week 48.
Sustained virological response was defined as undetectable
HCV-RNA levels in the serum at week 72 (i.e., 24 weeks after
the end of treatment, which was also the end of follow-up).
Patients whose viral load declinedmore slowly (<2log
10
drop
at week 12 as compared to baseline), those whose viral load
dropped >2log
10
at week 12 as compared to baseline and who
still had positive HCV-RNA at week 24, those who became
HCV-RNA positive after negativization before the end
of treatment (breakthrough response), and thosewho became
HCV-RNA positive after negativization at the end of treat-
ment (relapsers) were all considered non-SVRs.
2.2. Liver Histology. All patients underwent liver biopsy
within the 18 months prior to treatment. Paraffin embedded
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Table 1: Baseline metabolic parameters of 75 patients with genotype 1 chronic hepatitis C on the basis of gender.
All patients Male Female OR 95% CI 𝑃
Number of patients 75 45 30
Age (median; range) 49 (26–67) 48 (26–67) 49 (31–67) 1.01 (0.97–1.05) 0.58
BMI (median; range) 23.6 (19.4–29.6) 24.1 (21.3–29.6) 22.5 (19.4–28.7) 0.82 (0.68–0.99) 0.047
Fasting glucose (median; range) 5.03 (2.20–6.88) 5.10 (2.41–6.78) 4.83 (2.21–6.52) 0.82 (0.54–1.26) 0.37
Fasting insulin (median; range) 8.84 (1.4–27.9) 8.51 (1.40–21.3) 9.1 (2.0–33.1) 1.02 (0.97–1.08) 0.40
HOMA-IR (median; range) 1.9 (0.3–10.5) 1.9 (0.3–10.3) 2.05 (0.3–10.5) 1.09 (0.89–1.34) 0.42
Leptin (median; range) 9.2 (2.2–55) 6.3 (2.2–29.2) 15.4 (3–55) 1.14 (1.06–1.23) <0.000
Adiponectin (median; range) 13.5 (4.5–36.1) 12.2 (4.5–23.3) 17.05 (7.1–36.1) 1.16 (1.05–1.23) 0.002
biopsies were analyzed by a single pathologist unaware of
the clinical and biological data, except for the presence of
chronic hepatitis C. This analysis was performed after
hematoxylin-phloxin-safran, Perls, and picrosirius red stain-
ing. Liver biopsy specimens no less than 15mm long or the
presence of at least 10 complete portal tracts were required.
Necroinflammatory activity was graded and fibrosis was
staged according to Ishak’s scoring system [18]. Steatosis was
graded according to the percentage of hepatocytes containing
cytoplasmic vacuoles. It was demonstrated as >30% in 4
patients, between >5% and <30% in 7 patients and <5% in
the remaining 64 patients.
2.3. Clinical and Laboratory Determinations. Age, sex, and
body mass index (BMI, calculated as weight in kilograms/
height in squaremeters)were recorded for all patients at base-
line, while serum levels of ALT, aspartate aminotransferase
(AST), gamma-glutamyl transpeptidase (GGT), glucose (glu-
cose HK UV enzymatic test [Olympus]), insulin (measured
by a two-site immunoenzymometric assay (ST-AIA-PACK
IRI, Tosoh Corporation, Tokyo, Japan)), adoponectin, and
leptin (commercial radioimmunoassay, DRG diagnostics,
Germany) were all measured after overnight fasting. Glucose
levels were also determined at 2 hours after an oral glucose
intake of 75 grams (oral glucose tolerance test).
Insulin resistance was determined by the homeostasis
model assessment (HOMA) method using the following
equation: HOMA-IR = fasting insulin (mIU/L) × fasting
glucose (mmol/L)/22.5 [19]. HOMA-IR has been validated in
comparison with the euglycemic/hyperinsulinemic clamp
technique as the standard reference in both diabetic and
nondiabetic patients [20]. HOMA-IR, serum leptin, and BMI
were measured in all patients at baseline and at weeks 12 and
48.
2.4. Statistical Analysis. Databasemanagement and statistical
analyses were performed using a statistical software pack-
age (SPSS 10.0.5). Univariate analysis was carried out on
metabolic variables for their possible association with SVR.
𝑡-test or Pearson’s correlation test (for continuous variables)
and 𝑋2 test (for categorical variables) were used. Pearson’s
correlation test was also used to assess the association among
metabolic variables. Logistic regression was carried out for
multivariate analysis and for the definition of relative risk
Table 2: Mean baseline BMI, adiponectin, and leptin levels based
on quartiles distribution of HOMA-IR.
HOMA-IR quartiles 1
∘ 2∘ 3∘ 4∘
0.3–1.0 1.1–1.8 1.9–3.2 3.3–10.5
BMI 22.6 23.5 25.0 25.1
Leptin 7.0 10.5 13.9 20.7
Adiponectin 14.9 14.4 16.4 16.0
of single variables. A 𝑃 value less than 0.05 was considered
statistically significant.
3. Results
Of 75 patients (45males and 30 females), median age 48 years
(range 26–67), 26 experienced SVR (34.7%). Table 1 shows
some baseline metabolic parameters in the whole population
and the difference on the basis of gender. BMI was high in
men, whereas leptin and adiponectin were significantly
higher inwomen than inmen.No variation ofHOMA-IRwas
seen with regard to gender.
When we evaluated the influence of each variable against
each one of the others, we found a significant association
between HOMA-IR and both BMI (𝑃 = 0.010) and leptin
(𝑃 = 0.000), but not between HOMA-IR and age (𝑃 = 0.59)
or baseline adiponectin (𝑃 = 0.53).The same associations are
shown in Table 2 as the relationship of baseline BMI, adi-
ponectin, and leptin based on quartiles distribution.
Table 3 shows the association between baseline pretreat-
ment variables and SVR. Only age and BMI, but not HOMA-
IR, were significantly associated with SVR. Both age and BMI
were also independently associated with SVR at multivariate
analysis (OR 1.26; 95% CI 0.99–1.60; 𝑃 = 0.051 and OR 1.05;
95% CI 1–00–1.11; 𝑃 = 0.041, resp.), although the significance
of age is weak.
We also assessed the quartile distribution of HOMA-IR,
assuming the 75th percentile of HOMA-IR value, equal to
3.20, as the cut-off value of insulin resistance in our popu-
lation. The patients in the top quartile of HOMA-IR distri-
bution values who were classified as having insulin resistance
showed no difference in SVR rates (36.8%) compared with
patients in the other three quartiles ofHOMA-IR (33.9%; 95%
CI 0.29–2.60; 𝑃 = 0.81).
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Table 3: Baseline pretreatment variables based on treatment outcome (SVR) at univariate and multivariate analyses.
Univariate analysis Multivariate analysis
SVR Non-SVR OR 95% CI 𝑃 OR 95% CI 𝑃
Number of patients 26 49
Age (median; range) 48 (26–67) 49 (31–67) 1.07 (1.02–1.12) 0.008 1.26 (0.99–1.60) 0.051
Sex (M/F) 16/10 29/20 0.91 (0.34–2.4) 0.84
BMI (median; range) 22.7 (19.4–29.1) 24.2 (21.3–29.6) 1.33 (1.07–1.66) 0.01 1.05 (1.00–1.11) 0.041
Fasting glucose (median; range) 4.86 (2.41–6.23) 5.1 (2.2–6.88) 1.16 (0.76–1.79) 0.49
Fasting insulin (median; range) 8.0 (1.41–24.1) 8.9 (2.90–33.1) 0.98 (0.93–1.04) 0.58
HOMA-IR (median; range) 1.93 (0.3–10.3) 2.25 (0.3–10.5) 0.95 (0.77–1.18) 0.65
Leptin (median; range) 6.3 (2.2–29.2) 15.4 (3–55) 1.01 (0.96–1.05) 0.89
Adiponectin (median; range) 12.2 (4.5–23.3) 17.05 (7.1–36.1) 1.02 (0.94–1.10) 0.67
Table 4: On treatment HOMA-IR, BMI, and serum leptin variations based on early viral decay (EVR versus non-EVR).
EVR (𝑛 = 36) Non-EVR (𝑛 = 39)
Baseline 12 weeks 48 weeks Baseline 12 weeks 48 weeks
HOMA-IR (median) 2.03 (0.3–5.6) § 1.41 (0.33–3.35) 𝜓 1.60 (0.42–4.18) 2.30 (0.4–10.5) ∧ 2.18 (0.45–10.3) ∧ 2.21 (0.81–9.23)
BMI (median) 22.9 (19.4–29.1) ∧ 21.6 (19.4–29) ∧ 21.9 (20–29.1) 24 (21.5–29.6) ∧ 22.7 (20.3–29.1) ∧ 22.6 (19.6–29)
Serum leptin (median) 10.5 (3.8–27.9) ∧ 8.91 (3.3–39.6) ∧ 12.6 (2.6–35.7)\ 10.15 (3–25.6) ∧ 9.05 (3.8–25.7) ∧ 9.70 (3.2–23.2)
§(12 weeks versus baseline): 𝑃 = 0.033; 𝜓(48 weeks versus baseline): 𝑃 = 0.048; ∧(12 weeks versus baseline and 48 weeks versus baseline): 𝑃 = NS. EVR: early
viral response.
3.1. Variations in Metabolic Parameters during Treatment.
As reported in Table 3, baseline HOMA-IR was not signifi-
cantly different in patients who achieved SVR compared to
those who did not achieve SVR. However, when we assessed
HOMA-IR variations during treatment on the basis of dif-
ferent kinetics of viral load decay, we found a significant
reduction of HOMA-IR values at week 12 and a still but
weakly significant reduction at week 48 from baseline in the
EVR (𝑃 = 0.033 and 0.048, resp.) but not in the non-EVR
groups (Table 4).
We also analyse the variations of BMI and serum leptin
during treatment; two variable sproved to be significantly
associated with HOMA-IR. However, no significant varia-
tions of both variables at weeks 12 and 48 were observed
compared to baseline in the EVR versus non-EVR groups
(Table 4).
4. Discussion
Chronic hepatitis C virus infection is now considered a
metabolic disease due to its complex interaction with glucose
metabolism, leading to insulin resistance (IR) and diabetes.
Insulin resistance occurs very early in transgenic mice
expressing the HCV core protein (8), and this is similarly
observed in humans [21]. HCV is able to interfere with
the insulin signaling pathway by downregulating the insulin
receptor substrates 1 and 2 (IRS1/2) gene expression in liver
tissue [22]. On the other hand, there is robust evidence that
viral clearance improves insulin resistance in patients with
chronic hepatitis C with genotype 1 [12], which clearly
represents in vivo demonstration of genotype 1 HCV-induced
insulin resistance.
Since 2005, low SVR rates in patients with chronic
hepatitis C and insulin resistance (defined as HOMA-IR ≥ 2)
have been reported, and two meta-analyses reinforced this
observation [23, 24]. However, some considerations have to
be made: many of the studies that are included in these meta-
analyses are heterogeneous and include varying proportions
of patients with metabolic risk factors. In these studies,
different and often arbitrary cut-off values of HOMA-IR were
reported. Furthermore, as outlined by Eslam and colleagues,
colinearity between HOMA-IR and other metabolic vari-
ables and the characteristics of the patients may represent
strong confounders when analysing data [24]. Regarding the
characteristics of the patients, liver fibrosis is crucial in nega-
tively influencing SVR. However, insulin resistance is directly
involved in fibrogenesis and it is associated with more severe
fibrosis in genotype 1 patients [10]. Thus, liver fibrosis is
another confounding factor contributing to lower SVR rates
in patients with high HOMA-IR [23].
In our study, however, HOMA-IRwas not associated with
SVR. One reason could be related to patient selection. Our
cohort did not include patients with advanced fibrosis nor
those with high HOMA-IR values (median 1.9) or high BMI
(median 23.6), a feature that is in line with the observation by
Eslam and colleagues. In fact, of all the studies in their meta-
analysis which failed to find an association between insulin
resistance and SVR, the mean baseline HOMA-IR was <3
and the prevalence of advanced fibrosis or cirrhosis was also
low or even absent [24]. This observation supports the idea
thatHOMA-IR is predictive of response to antiviral treatment
only in patients with metabolic risk factors or advanced
fibrosis, whereas in those without metabolic risk factors or
with lower fibrosis and in whom insulin resistance is mainly
HCV-related, the HOMA-IR index is improved by antiviral
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treatment and has no impact on response [23]. A study of
Fattovich and colleagues [25] seems to further confirm this
hypothesis. In this study, insulin resistance, regardless of the
method used to measure it, failed to predict viral response
in patients with chronic hepatitis C without metabolic syn-
drome.
When we evaluated the difference in HOMA-IR values
at baseline, at week 12 and at the end of treatment on the
basis of viral kinetics, we observed a rapid decrease (week 12)
of HOMA-IR value followed by a slight increase at the end of
treatment (week 48) only in the group of patients with early
viral abatement (EVR). This observation suggests an imbal-
ance of the metabolic pathway in the early phase of treatment
in patients who are unable to suppress viral replication.
Many studies seem to support this hypothesis. Bortoletto
and colleagues demonstrated that insulin resistance exerts its
negative influence on viral decay very early, already in the first
24-hours after starting antiviral treatment [13]. On the other
hand, high HOMA-IR values have been associated with low
rates of rapid viral response (RVR) in genotypes 1 [26], 3 [27]
and 4 [28].
The possible link between HCV infection, insulin resis-
tance, and the early phase of viral kinetics during antiviral
treatment involves the downregulation of IRS1/2 and upreg-
ulation of the suppressor of cytokine signaling-3 (SOCS-3)
genes in liver tissue [9, 22]. SOCS-3 is a gene involved in
the interferon signaling pathway and it is associated with
poorer treatment outcome in patients with chronic hepatitis
C viral genotype 1. Its overexpression is also associated with
metabolic syndrome [29]. In this view, it could be specu-
lated that, in patients with genotype 1-chronic hepatitis C
without metabolic risk factors and in those whomwe assume
there is anHCV-related insulin resistance, HOMA-IRmay be
considered a surrogatemarker of genotype 1b-induced upreg-
ulation of the SOCS3 gene in nonresponders to antiviral
treatment.
Many studies have tried to demonstrate the beneficial
effect of adding insulin sensitiser agents to peginterferon and
ribavirin in order to enhance viral clearance in genotype 1
chronic hepatitis C with insulin resistance. Neither met-
formin nor pioglitazone proved the validity of this therapeu-
tic strategy in the attempt to achieve SVR, although higher
early viral response (at 4 and 12 weeks) was observed in the
insulin sensitizer plus peginterferon and ribavirin groups
compared with the control groups (peginterferon plus rib-
avirin) [30–32]. The results of these studies confirm that
insulin resistance in genotype 1-HCV patients is the result of
a more complex pathogenetic interrelation that is only
marginally influenced by the activation of the proliferator-
activated receptor-𝛾 (PPAR-𝛾) pathway or via themetformin-
induced hepatic AMP-activated protein kinase.
One of the goals of this study was to explore the associa-
tion of somemetabolic variables with insulin resistance. First,
we found a different association with gender among various
metabolic variables. No differences in HOMA-IR were
observed between males and females, whereas BMI was
higher in males. Although we expected higher leptin levels in
males based on BMI, we found higher levels of both leptin
and adiponectin in females. This observation was already
reported by Lo Iacono and colleagues [17] andwas found to be
related to a higher grade of steatosis. Although this data was
not assessed in our population due to a low prevalence of
significant steatosis (only 11 out of 75 patients had steatosis in
more than 5%of hepatocytes) a slight increase of serum leptin
in female with higher degree of steatosis was observed.
Furthermore, our study is aimed at exploring whether
HOMA-IR variations during antiviral treatment are asso-
ciated with similar variations in leptin and BMI or not.
Althoughwe assessed both leptin and adiponectin at baseline,
we chose to compare only leptin variations during treatment
because only leptin and BMI, but not adiponectin, were
associated with HOMA-IR.
Leptin is a 16-kDa polypeptide that is synthesized
by mature adipocytes, skeletal muscle cells, and culture-
activated hepatic stellate cells. Leptin expression is regulated
by IL-1, TNF-𝛼, and insulin, whereas its secretion, a prerog-
ative of adipocytes alone, is proportional to the fat mass and
provides antiobesity signals. Nonetheless, obese patients have
elevated levels of leptin, suggesting that they are resistant to
its action. One of the mechanisms of leptin resistance is an
increase in SOCS3 levels, which impairs postreceptor sig-
naling and leads to reduced adenosine monophosphate-
activated protein kinase (AMPK) activation [33].
In our study, we observed no significant variations in
either BMI or in leptin levels between baseline and weeks 12
and 48, unlike HOMA-IR.This issue seems to further suggest
a selective effect of treatment on HCV-related insulin resis-
tance. More information needs to be obtained by comparing
insulin resistance to leptin levels during long-term follow-up
after treatment.
Furthermore, unlike what was reported by Conjeevaram
and colleagues [15], we did not observe a similar variation of
HOMA-IR and BMI during treatment. However, our study
population is not comparable to that of Conjeevaram et al.’s
study in which BMI was above 25 in more than 77% of
patients.
In summary, in our selected population of noncirrhotic,
nonobese, and nondiabetic HCV chronic patients, HOMA-
IR, as expression of insulin resistance, is not a predictor of
SVR but rather a dynamic parameter influenced by viral load.
In fact, its significant reduction in parallel with a consistent
abatement of viral load during antiviral treatment (EVR
patients) compared with patients who did not achieve signifi-
cant drop in viral load (non-EVR) suggests that the viral load
has a role in determining a state of “inflammatory” insulin
resistance, irrespective of BMI and leptin levels.
In conclusion, our data support the hypothesis of a viral-
related insulin resistance in chronic hepatitis C genotype 1
patients without a metabolic phenotype.
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